AI stock analysis · Biotechnology · Last analyzed Jul 8, 2026
Compass Score
3.0/5
Call
Hold
Price
$11.91
AI Target
$31.17 +161.6%
AI Analyst Summary
Kura Oncology is a clinical-stage biotech generating outsized analyst conviction — a near-unanimous Strong Buy consensus from 15 analysts and a consensus price target implying ~162% upside — driven by its pipeline of tipifarnib and ziftomenib targeting rare hematologic malignancies with significant unmet need. Revenue growth of 29.5% YoY signals early commercial or partnership momentum, and ziftomenib's potential NDA filing in NPM1-mutant AML represents a near-term value inflection point. The key risk is the company's pre-profitability status, with a 0-of-3 recent EPS beat rate indicating persistent cost overruns relative to expectations and no visible near-term path to positive earnings.
Catalysts
Potential NDA submission and FDA review of ziftomenib for NPM1-mutant relapsed/refractory AML, which could serve as a major de-risking and valuation catalyst in the near term.
Updated clinical data readouts from the KOMET-001 trial for ziftomenib, with response rates and durability metrics capable of moving the stock materially on presentation at oncology conferences.
Potential partnership, licensing, or co-development deal leveraging the tipifarnib or ziftomenib programs, which could provide non-dilutive capital and validate pipeline value.
Fundamentals
PeN/A (loss-making) · 1.0/5
No trailing P/E available; forward P/E is deeply negative at -4.6x, reflecting a pre-profitability clinical-stage biotech with no earnings base to value.
PegN/A · 3.0/5
PEG ratio is unavailable due to negative earnings. Scored neutral per guidelines for missing PEG in a loss-making company.
Analyst RatingStrong Buy consensus (1.3) · 5.0/5
Consensus of 1.3 from 15 analysts (14 Buy / 1 Hold / 0 Sell) maps to the highest score tier (1.0–1.5). Broad, high-conviction bullish sentiment across a meaningful analyst base.
Earnings growth is not applicable for a pre-revenue clinical-stage biotech. Revenue growth of 29.5% YoY is encouraging but the company remains deeply loss-making with no near-term path to profitability signaled.
Price Target Beat0 of 3 quarters beat · 1.0/5
EPS beat rate of 0 out of the last 3 quarters is a red flag for execution consistency, suggesting the company has consistently missed consensus EPS estimates, likely due to rising R&D and clinical spend.
ManagementMixed — high analyst confidence, poor near-term execution · 3.0/5
Strong analyst backing suggests confidence in the pipeline and strategic direction, but the 0-of-3 EPS beat rate points to inconsistent near-term financial execution. Scored neutral given the offset between strategic credibility and operational delivery.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.